Open AccessA Review of Cisplatin-Associated Ototoxicity
Author(s) -
Jessica Paken,
Cyril D. Govender,
Mershen Pillay,
Vikash Sewram
Publication year - 2019
Publication title -
seminars in hearing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.592
H-Index - 27
eISSN - 1098-8955
pISSN - 0734-0451
DOI - 10.1055/s-0039-1684041
Subject(s) - ototoxicity , medicine , cisplatin , hearing loss , intensive care medicine , quality of life (healthcare) , audiology , chemotherapy , nursing
Cisplatin, an effective antineoplastic drug used in the treatment of many cancers, has ototoxic potential, thus placing cancer patients, receiving this treatment, at risk of hearing loss. It is therefore important for health care professionals managing these patients to be aware of cisplatin's ototoxic properties and its clinical signs to identify patients at risk of developing a hearing impairment. Eighty-five English peer-reviewed articles and two books, from January 1975 to July 2015, were identified from PubMed, ScienceDirect, and EBSCOhost. An overview of cisplatin-associated ototoxicity, namely its clinical features, incidence rates, molecular and cellular mechanisms, and risk factors, is presented in this article. This review further highlights the importance of a team-based approach to complement an audiological monitoring program in reducing any further loss in the quality of life of affected patients, as there is currently no otoprotective agent routinely recommended for the prevention of cisplatin-associated ototoxicity.